(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Lumen Technologies, Northern Trust, and Mercantile Bank Corporation.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Lumen Technologies (LUMN) | 1.89 | 16.36% | 2023-07-19 13:47:21 |
| 2 | Northern Trust (NTRS) | 81.43 | 13.57% | 2023-07-19 13:26:30 |
| 3 | Mercantile Bank Corporation (MBWM) | 33.03 | 12.16% | 2023-07-18 23:13:07 |
| 4 | PacWest Bancorp (PACW) | 9.95 | 11.3% | 2023-07-19 15:23:12 |
| 5 | Groupon (GRPN) | 7.51 | 9.48% | 2023-07-19 13:25:06 |
| 6 | NN (NNBR) | 2.66 | 9.02% | 2023-07-19 07:42:08 |
| 7 | AT&T (T) | 14.59 | 8.44% | 2023-07-19 13:45:13 |
| 8 | Omeros Corporation (OMER) | 5.76 | 8.07% | 2023-07-19 13:06:09 |
| 9 | Citizens Financial Group (CFG) | 31.41 | 7.9% | 2023-07-19 13:32:45 |
| 10 | Ocular Therapeutix (OCUL) | 4.84 | 7.68% | 2023-07-19 11:12:07 |
The three biggest losers today are Masimo Corporation, Redfin, and FibroGen.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Masimo Corporation (MASI) | 117.73 | -20% | 2023-07-18 22:55:32 |
| 2 | Redfin (RDFN) | 14.76 | -7.4% | 2023-07-19 13:30:20 |
| 3 | FibroGen (FGEN) | 2.39 | -6.64% | 2023-07-19 13:24:31 |
| 4 | Super Micro Computer (SMCI) | 299.69 | -5.88% | 2023-07-19 13:27:22 |
| 5 | Align Technology (ALGN) | 342.00 | -5.16% | 2023-07-19 13:22:34 |
| 6 | ASML Holding (ASML) | 718.59 | -5.08% | 2023-07-19 13:22:57 |
| 7 | Neptune Wellness Solutions (NEPT) | 0.14 | -5.02% | 2023-07-19 07:10:08 |
| 8 | Arcturus Therapeutics (ARCT) | 35.51 | -4.93% | 2023-07-19 13:28:28 |
| 9 | Interactive Brokers Group (IBKR) | 82.63 | -4.22% | 2023-07-19 13:25:22 |
| 10 | QuantumScape (QS) | 10.13 | -4.06% | 2023-07-19 13:47:19 |
Winners today
1. Lumen Technologies (LUMN) – 16.36%
Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.
NYSE ended the session with Lumen Technologies rising 16.36% to $1.89 on Wednesday, after five sequential sessions in a row of losses. NYSE jumped 0.46% to $16,230.94, after two sequential sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Lumen Technologies has a trailing twelve months EPS of $-1.61.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumen Technologies’s stock is considered to be overbought (>=80).
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 200% and a negative 50%, respectively.
More news about Lumen Technologies.
2. Northern Trust (NTRS) – 13.57%
Northern Trust Corporation, a financial holding company, provides wealth management, asset servicing, asset management, and banking solutions for corporations, institutions, families, and individuals worldwide. It operates in two segments, Asset Servicing and Wealth Management. The Asset Servicing segment offers asset servicing and related services, including custody, fund administration, investment operations outsourcing, investment management, investment risk and analytical services, employee benefit services, securities lending, foreign exchange, treasury management, brokerage services, transition management services, banking, and cash management services. This segment serves corporate and public retirement funds, foundations, endowments, fund managers, insurance companies, sovereign wealth funds, and other institutional investors. The Wealth Management segment offers trust, investment management, custody, and philanthropic; financial consulting; guardianship and estate administration; family business consulting; family financial education; brokerage services; and private and business banking services. This segment serves high-net-worth individuals and families, business owners, executives, professionals, retirees, and established privately held businesses. The company also provides asset management services, such as active and passive equity; active and passive fixed income; cash management; alternative asset classes comprising private equity and hedge funds of funds; and multi-manager advisory services and products through separately managed accounts, bank common and collective funds, registered investment companies, exchange traded funds, non-U.S. collective investment funds, and unregistered private investment funds. In addition, it offers overlay and other risk management services. Northern Trust Corporation was founded in 1889 and is headquartered in Chicago, Illinois.
NASDAQ ended the session with Northern Trust jumping 13.57% to $81.43 on Wednesday while NASDAQ rose 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Northern Trust has a trailing twelve months EPS of $5.78.
PE Ratio
Northern Trust has a trailing twelve months price to earnings ratio of 14.09. Meaning, the purchaser of the share is investing $14.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.14%.
Volume
Today’s last reported volume for Northern Trust is 4692300 which is 235.29% above its average volume of 1399480.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 12.9% and a negative 13.3%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.8%, now sitting on 6.76B for the twelve trailing months.
More news about Northern Trust.
3. Mercantile Bank Corporation (MBWM) – 12.16%
Mercantile Bank Corporation operates as the bank holding company for Mercantile Bank of Michigan that provides commercial and retail banking services for small- to medium-sized businesses and individuals in the United States. It accepts various deposit products, including checking, savings, and term certificate accounts; time deposits; and certificates of deposit. The company also offers commercial, residential mortgage, and instalment loans; vacant land, land development, and residential construction loans; owner and non-owner occupied, and multi-family and residential rental property real estate loans; single-family residential real estate loans; home equity line of credit programs; and consumer loans, such as loans for new and used automobiles, boats, and credit cards, as well as overdraft protection services. In addition, it provides courier services and safe deposit facilities; repurchase agreements; and insurance products, such as private passenger automobile, homeowners, personal inland marine, boat owners, recreational vehicle, dwelling fire, umbrella policies, small business, and life insurance products, as well as owns 27 automated teller machines and 13 video banking machines. The company operates 44 banking offices. Mercantile Bank Corporation was incorporated in 1997 and is headquartered in Grand Rapids, Michigan.
NASDAQ ended the session with Mercantile Bank Corporation rising 12.16% to $33.03 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Mercantile Bank Corporation has a trailing twelve months EPS of $4.43.
PE Ratio
Mercantile Bank Corporation has a trailing twelve months price to earnings ratio of 7.46. Meaning, the purchaser of the share is investing $7.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.61%.
More news about Mercantile Bank Corporation.
4. PacWest Bancorp (PACW) – 11.3%
PacWest Bancorp operates as the bank holding company for Pacific Western Bank that provides various banking products and services. The company accepts demand, money market, and time deposits. It also provides real estate loans to professional developers and real estate investors for the acquisition, refinancing, renovation, and construction of commercial real estate properties; small business administration loans; asset-based loans for working capital needs; venture capital loans to support the operations of entrepreneurial and venture-backed companies; and equipment-secured loans and leases. In addition, the company offers consumer loans comprising personal loans, auto loans, home equity lines of credit, revolving lines of credit, and other loans. Further, it provides international banking and multi-state deposit services; money market sweep products; investment advisory and asset management services; treasury and cash management services; telephone banking, remote deposit, and online and mobile banking services; and automated teller machine services. The company offers its products and services to small and mid-sized companies, venture capital and private equity investors, professionals, and other individuals. As of February 1, 2022, it operated through 69 full-service branches located in California; one branch located in Durham, North Carolina; one branch located in Denver, Colorado; and various loan production offices. The company was formerly known as First Community Bancorp and changed its name to PacWest Bancorp in April 2008. PacWest Bancorp was founded in 1999 and is headquartered in Beverly Hills, California.
NASDAQ ended the session with PacWest Bancorp jumping 11.3% to $9.95 on Wednesday while NASDAQ rose 0.03% to $14,358.02.
Earnings Per Share
As for profitability, PacWest Bancorp has a trailing twelve months EPS of $-7.24.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.78%.
Yearly Top and Bottom Value
PacWest Bancorp’s stock is valued at $9.95 at 17:32 EST, way under its 52-week high of $30.43 and way above its 52-week low of $2.48.
Moving Average
PacWest Bancorp’s value is way higher than its 50-day moving average of $7.36 and way below its 200-day moving average of $17.71.
More news about PacWest Bancorp.
5. Groupon (GRPN) – 9.48%
Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.
NASDAQ ended the session with Groupon jumping 9.48% to $7.51 on Wednesday, after two successive sessions in a row of gains. NASDAQ rose 0.03% to $14,358.02, after two sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Groupon has a trailing twelve months EPS of $-7.66.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -285.15%.
Sales Growth
Groupon’s sales growth is negative 19.7% for the current quarter and negative 13.2% for the next.
Moving Average
Groupon’s value is way higher than its 50-day moving average of $5.03 and way above its 200-day moving average of $6.42.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Groupon’s EBITDA is -26.49.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Groupon’s stock is considered to be oversold (<=20).
More news about Groupon.
6. NN (NNBR) – 9.02%
NN, Inc., a diversified industrial company, designs, manufactures, and sells high-precision components and assemblies primarily for the electrical, automotive, general industrial, aerospace and defense, and medical markets. It operates through Mobile Solutions and Power Solutions segments. The Mobile Solutions segment manufactures and sells system critical components for fuel systems, engines and transmissions, power steering systems, and electromechanical motors for general industrial and automotive end markets. The Power Solutions segment designs, manufactures, and sells a range of high-precision metal and plastic components, assemblies, and finished devices used in applications ranging from power control to flight control and for military devices. Its products include electrical contacts, connectors, contact assemblies, and precision stampings for the electrical end market; and high precision products for the aerospace and defense end markets. This segment also produces various tools and instruments for the orthopaedics and medical/surgical end markets. The company sells its products worldwide primarily to manufacturers directly. NN, Inc. was founded in 1980 and is headquartered in Charlotte, North Carolina.
NASDAQ ended the session with NN rising 9.02% to $2.66 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, NN has a trailing twelve months EPS of $-0.96.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.42%.
Moving Average
NN’s worth is way higher than its 50-day moving average of $1.93 and way higher than its 200-day moving average of $1.76.
More news about NN.
7. AT&T (T) – 8.44%
AT&T Inc. provides telecommunications and technology services worldwide. The company operates through two segments, Communications and Latin America. The Communications segment offers wireless voice and data communications services; and sells handsets, wireless data cards, wireless computing devices, and carrying cases and hands-free devices through its own company-owned stores, agents, and third-party retail stores. It also provides Virtual Private Networks, AT&T Dedicated Internet, Ethernet, data services, security, cloud solutions, outsourcing, and managed and professional services, as well as customer premises equipment for multinational corporations, small and mid-sized businesses, governmental, and wholesale customers. In addition, this segment offers broadband services, including fiber connections and legacy telephony voice communication services to residential customers. This segment markets its communications services and products under the AT&T, Cricket, AT&T PREPAID, and AT&T Fiber brand names. The Latin America segment provides postpaid and prepaid wireless services in Mexico under the AT&T and Unefon brand names, as well as sells smartphones through its owned stores, agents and third-party retail stores. The company was formerly known as SBC Communications Inc. and changed its name to AT&T Inc. in 2005. AT&T Inc. was incorporated in 1983 and is based in Dallas, Texas.
NYSE ended the session with AT&T jumping 8.44% to $14.59 on Wednesday while NYSE rose 0.46% to $16,230.94.
Earnings Per Share
As for profitability, AT&T has a trailing twelve months EPS of $-1.18.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.13%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
AT&T’s EBITDA is 23.84.
Volatility
AT&T’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.24%, a negative 0.80%, and a positive 1.46%.
AT&T’s highest amplitude of average volatility was 5.24% (last week), 1.43% (last month), and 1.46% (last quarter).
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 6, 2023, the estimated forward annual dividend rate is 1.11 and the estimated forward annual dividend yield is 7.66%.
Volume
Today’s last reported volume for AT&T is 107508000 which is 135.97% above its average volume of 45558600.
More news about AT&T.
8. Omeros Corporation (OMER) – 8.07%
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Omeros Corporation jumping 8.07% to $5.76 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Omeros Corporation has a trailing twelve months EPS of $-2.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -728.71%.
Moving Average
Omeros Corporation’s value is below its 50-day moving average of $5.86 and way above its 200-day moving average of $4.12.
Volume
Today’s last reported volume for Omeros Corporation is 367745 which is 46.04% below its average volume of 681613.
Yearly Top and Bottom Value
Omeros Corporation’s stock is valued at $5.76 at 17:32 EST, way below its 52-week high of $7.80 and way above its 52-week low of $1.74.
More news about Omeros Corporation.
9. Citizens Financial Group (CFG) – 7.9%
Citizens Financial Group, Inc. operates as the bank holding company for Citizens Bank, National Association that provides retail and commercial banking products and services to individuals, small businesses, middle-market companies, corporations, and institutions in the United States. The company operates in two segments, Consumer Banking and Commercial Banking. The Consumer Banking segment offers deposit products, mortgage and home equity lending products, credit cards, business loans, wealth management, and investment services; and auto, education, and point-of-sale finance loans, as well as digital deposit products. This segment serves its customers through telephone service centers, as well as through its online and mobile platforms. The Commercial Banking segment provides various financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, and interest rate and commodity risk management solutions, as well as syndicated loans, corporate finance, mergers and acquisitions, and debt and equity capital markets services. This segment serves government banking, not-for-profit, healthcare, technology, professionals, oil and gas, asset finance, franchise finance, asset-based lending, commercial real estate, private equity, and sponsor finance industries. The company was formerly known as RBS Citizens Financial Group, Inc. and changed its name to Citizens Financial Group, Inc. in April 2014. Citizens Financial Group, Inc. was founded in 1828 and is headquartered in Providence, Rhode Island.
NYSE ended the session with Citizens Financial Group jumping 7.9% to $31.41 on Wednesday while NYSE jumped 0.46% to $16,230.94.
Earnings Per Share
As for profitability, Citizens Financial Group has a trailing twelve months EPS of $4.02.
PE Ratio
Citizens Financial Group has a trailing twelve months price to earnings ratio of 7.81. Meaning, the purchaser of the share is investing $7.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.35%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 1, 2023, the estimated forward annual dividend rate is 1.68 and the estimated forward annual dividend yield is 5.92%.
More news about Citizens Financial Group.
10. Ocular Therapeutix (OCUL) – 7.68%
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
NASDAQ ended the session with Ocular Therapeutix jumping 7.68% to $4.84 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Ocular Therapeutix has a trailing twelve months EPS of $-1.17.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -198.45%.
Moving Average
Ocular Therapeutix’s value is way under its 50-day moving average of $5.82 and above its 200-day moving average of $4.67.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.4%, now sitting on 51.68M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 20% and positive 6.5% for the next.
Volume
Today’s last reported volume for Ocular Therapeutix is 505508 which is 61.6% below its average volume of 1316690.
More news about Ocular Therapeutix.
Losers Today
1. Masimo Corporation (MASI) – -20%
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
NASDAQ ended the session with Masimo Corporation dropping 20% to $117.73 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Masimo Corporation has a trailing twelve months EPS of $2.15.
PE Ratio
Masimo Corporation has a trailing twelve months price to earnings ratio of 54.76. Meaning, the purchaser of the share is investing $54.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.12%.
Moving Average
Masimo Corporation’s value is way under its 50-day moving average of $161.94 and way below its 200-day moving average of $159.33.
More news about Masimo Corporation.
2. Redfin (RDFN) – -7.4%
Redfin Corporation operates as a residential real estate brokerage company in the United States and Canada. The company operates an online real estate marketplace and provides real estate services, including assisting individuals in the purchase or sell of home. It also provides title and settlement services; and originates and sells mortgages. The company was formerly known as Appliance Computing Inc. and changed its name to Redfin Corporation in May 2006. Redfin Corporation was incorporated in 2002 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Redfin dropping 7.4% to $14.76 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Redfin has a trailing twelve months EPS of $-2.85.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -173.25%.
Moving Average
Redfin’s value is way higher than its 50-day moving average of $11.09 and way higher than its 200-day moving average of $7.57.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Redfin’s EBITDA is -48.92.
Sales Growth
Redfin’s sales growth is negative 54.7% for the ongoing quarter and negative 52.1% for the next.
More news about Redfin.
3. FibroGen (FGEN) – -6.64%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen falling 6.64% to $2.39 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.03% to $14,358.02, after two successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.15.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -411.93%.
Sales Growth
FibroGen’s sales growth is 16.6% for the ongoing quarter and 138% for the next.
Yearly Top and Bottom Value
FibroGen’s stock is valued at $2.39 at 17:32 EST, below its 52-week low of $2.39.
Revenue Growth
Year-on-year quarterly revenue growth declined by 40.6%, now sitting on 116.07M for the twelve trailing months.
More news about FibroGen.
4. Super Micro Computer (SMCI) – -5.88%
Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high performance server and storage solutions based on modular and open architecture in the United States, Europe, Asia, and internationally. Its solutions range from complete server, storage systems, modular blade servers, blades, workstations, full racks, networking devices, server sub-systems, server management software, and security software. The company also provides application-optimized server solutions, rackmount and blade servers, storage, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, SuperCloud Composer, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. It sells its products through direct and indirect sales force, distributors, value-added resellers, system integrators, and original equipment manufacturers. Super Micro Computer, Inc. was incorporated in 1993 and is headquartered in San Jose, California.
NASDAQ ended the session with Super Micro Computer sliding 5.88% to $299.69 on Wednesday while NASDAQ rose 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Super Micro Computer has a trailing twelve months EPS of $10.63.
PE Ratio
Super Micro Computer has a trailing twelve months price to earnings ratio of 28.19. Meaning, the purchaser of the share is investing $28.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.6%.
Yearly Top and Bottom Value
Super Micro Computer’s stock is valued at $299.69 at 17:32 EST, below its 52-week high of $306.85 and way higher than its 52-week low of $42.40.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.3%, now sitting on 6.57B for the twelve trailing months.
More news about Super Micro Computer.
5. Align Technology (ALGN) – -5.16%
Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, China, and internationally. It operates in two segments, Clear Aligner; and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; and non-case products that include retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment. The Systems and Services segment offers iTero intraoral scanning system, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, and pay per scan services Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
NASDAQ ended the session with Align Technology sliding 5.16% to $342.00 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.03% to $14,358.02, after two sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Align Technology has a trailing twelve months EPS of $4.07.
PE Ratio
Align Technology has a trailing twelve months price to earnings ratio of 84.03. Meaning, the purchaser of the share is investing $84.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.82%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.1%, now sitting on 3.7B for the twelve trailing months.
Moving Average
Align Technology’s value is above its 50-day moving average of $315.89 and way higher than its 200-day moving average of $273.09.
Sales Growth
Align Technology’s sales growth is 2.4% for the current quarter and 4.1% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Align Technology’s stock is considered to be overbought (>=80).
More news about Align Technology.
6. ASML Holding (ASML) – -5.08%
ASML Holding N.V. develops, produces, markets, sells, and services advanced semiconductor equipment systems consisting of lithography, metrology, and inspection systems for memory and logic chipmakers. The company provides extreme ultraviolet lithography systems; and deep ultraviolet lithography systems comprising immersion and dry lithography solutions to manufacture various range of semiconductor nodes and technologies. It also offers metrology and inspection systems, including YieldStar optical metrology solutions to assess the quality of patterns on the wafers; and HMI e-beam solutions to locate and analyze individual chip defects. In addition, the company provides computational lithography and lithography process and control software solutions; and refurbishes and upgrades older lithography systems, as well as offers customer support and associated services. It operates in Japan, South Korea, Singapore, Taiwan, China, rest of Asia, the Netherlands, rest of Europe, the Middle East, Africa, and the United States. The company was formerly known as ASM Lithography Holding N.V. and changed its name to ASML Holding N.V. in 2001. ASML Holding N.V. was founded in 1984 and is headquartered in Veldhoven, the Netherlands.
NASDAQ ended the session with ASML Holding dropping 5.08% to $718.59 on Wednesday, after five successive sessions in a row of gains. NASDAQ rose 0.03% to $14,358.02, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, ASML Holding has a trailing twelve months EPS of $19.3.
PE Ratio
ASML Holding has a trailing twelve months price to earnings ratio of 37.23. Meaning, the purchaser of the share is investing $37.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 74.04%.
Yearly Top and Bottom Value
ASML Holding’s stock is valued at $718.59 at 17:32 EST, under its 52-week high of $771.98 and way higher than its 52-week low of $363.15.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 30, 2023, the estimated forward annual dividend rate is 9.96 and the estimated forward annual dividend yield is 1.33%.
Previous days news about ASML Holding
- ASML holding (asml) to post Q2 earnings: what's in the cards?. According to Zacks on Monday, 17 July, "Our proven model does not conclusively predict an earnings beat for ASML Holding this time around. "
More news about ASML Holding.
7. Neptune Wellness Solutions (NEPT) – -5.02%
Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Neutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.
NASDAQ ended the session with Neptune Wellness Solutions falling 5.02% to $0.14 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Neptune Wellness Solutions has a trailing twelve months EPS of $-5.12.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -533.72%.
More news about Neptune Wellness Solutions.
8. Arcturus Therapeutics (ARCT) – -4.93%
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
NASDAQ ended the session with Arcturus Therapeutics sliding 4.93% to $35.51 on Wednesday while NASDAQ jumped 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $4.3.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 8.26. Meaning, the purchaser of the share is investing $8.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.3%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Arcturus Therapeutics’s stock is considered to be oversold (<=20).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Arcturus Therapeutics’s EBITDA is 23.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1431%, now sitting on 281.04M for the twelve trailing months.
Sales Growth
Arcturus Therapeutics’s sales growth is 64.2% for the present quarter and 455% for the next.
More news about Arcturus Therapeutics.
9. Interactive Brokers Group (IBKR) – -4.22%
Interactive Brokers Group, Inc. operates as an automated electronic broker worldwide. The company specializes in routing, executing, and processing trades in stocks, options, futures, foreign exchange instruments, bonds, mutual funds, exchange traded funds (ETFs), metals, and cryptocurrencies. It also custodies and services accounts for hedge and mutual funds, ETFs, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. In addition, it offers custody, prime brokerage, securities, and margin lending services. The company serves institutional and individual customers through approximately 150 electronic exchanges and market centers. Interactive Brokers Group, Inc. was founded in 1977 and is headquartered in Greenwich, Connecticut.
NASDAQ ended the session with Interactive Brokers Group falling 4.22% to $82.63 on Wednesday while NASDAQ rose 0.03% to $14,358.02.
Earnings Per Share
As for profitability, Interactive Brokers Group has a trailing twelve months EPS of $2.84.
PE Ratio
Interactive Brokers Group has a trailing twelve months price to earnings ratio of 29.13. Meaning, the purchaser of the share is investing $29.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.16%.
Yearly Top and Bottom Value
Interactive Brokers Group’s stock is valued at $82.63 at 17:32 EST, below its 52-week high of $90.19 and way above its 52-week low of $54.86.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 0.47%.
More news about Interactive Brokers Group.
10. QuantumScape (QS) – -4.06%
QuantumScape Corporation, a development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. QuantumScape Corporation was founded in 2010 and is headquartered in San Jose, California.
NYSE ended the session with QuantumScape falling 4.06% to $10.13 on Wednesday, after four successive sessions in a row of gains. NYSE jumped 0.46% to $16,230.94, after two consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Quantumscape (qs) to report Q2 earnings: here's what to expectAs per its pre-established target, QuantumScape started shipping 24-layer A0 cells to customers at the end of 2022. , Our proven model doesn’t conclusively predict an earnings beat for QuantumScape for the to-be-reported quarter as it does not have the right combination of the two key ingredients.
Earnings Per Share
As for profitability, QuantumScape has a trailing twelve months EPS of $-0.99.
Volatility
QuantumScape’s last week, last month’s, and last quarter’s current intraday variation average was 0.37%, 1.62%, and 3.61%.
QuantumScape’s highest amplitude of average volatility was 2.40% (last week), 3.54% (last month), and 3.61% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 4.5% and 18.5%, respectively.
More news about QuantumScape.
Stay up to date with our winners and losers daily report
